Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.06

-0.9%

10:00 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oak Tree who wrote (3018)	3/15/2001 4:26:11 PM
From: Jibacoa	Read Replies (1) of 52153

Will drug eluting stents cause an early demise of the recently approved beta & gamma radiation therapies ? Jeffery Popma,M.D, from Brigham and Women's Hosp. and Patrick W.Serruys M.D. from Erasmus Univ. in Rotterdam have been reporting good results with the drug-eluting stents (like Quanam's QuaDS) Since they don't require any special technique or equipment, they feel that the new stents will gradually displace the use of brachytherapy. In the mean time NOVT stock has to deal with the nearest resistance in the 35 area before it could try for the double top at the 39 1/2 level. siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next